Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
Other Sizes |
|
Purity: ≥98%
Trazodone HCl (Beneficat, KB 831, KB831, AF 1161, AF1161), the hydrochloride salt of Trazodone, is an approved antidepressant drug of the class of serotonin receptor antagonists and reuptake inhibitors (SARI) with the potential for treatment of anxiety disorders. It has anti-anxiety (anxiolytic) and sleep-inducing (hypnotic) properties. It is chemically a phenylpiperazine analog. It differs significantly from the original antidepressants, such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs), in terms of side-effect profile and potential toxicity.
Molecular Formula |
C19H23CL2N5O
|
|
---|---|---|
Molecular Weight |
408.32
|
|
Exact Mass |
371.15
|
|
Elemental Analysis |
C, 55.89; H, 5.68; Cl, 17.36; N, 17.15; O, 3.92
|
|
CAS # |
25332-39-2
|
|
Related CAS # |
Trazodone-d6 hydrochloride; 1181578-71-1; Trazodone; 19794-93-5
|
|
Appearance |
White to off-white crystalline powder
|
|
SMILES |
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl
|
|
InChi Key |
OHHDIOKRWWOXMT-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C19H22ClN5O.ClH/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25;/h1-3,5-7,9,15H,4,8,10-14H2;1H
|
|
Chemical Name |
2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4491 mL | 12.2453 mL | 24.4906 mL | |
5 mM | 0.4898 mL | 2.4491 mL | 4.8981 mL | |
10 mM | 0.2449 mL | 1.2245 mL | 2.4491 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04468776 | Active Recruiting |
Drug: Zolpidem Drug: Trazodone |
Chronic Insomnia | California Pacific Medical Center Research Institute |
February 25, 2022 | Phase 4 |
NCT05307003 | Recruiting | Drug: Trazodone Drug: Quetiapine |
Delirium Psych |
University of Southern California |
April 1, 2023 | N/A |
NCT05299398 | Not yet recruiting | Drug: Trazodone Drug: Placebo |
Postpartum Depression | Verinder Sharma | September 1, 2022 | Phase 1 |
NCT05085808 | Not yet recruiting | Drug: Trazodone Drug: Quetiapine |
Delirium Morality |
University of Southern California |
March 1, 2024 | Phase 4 |
NCT03668041 | Recruiting | Drug: Trazodone Drug: Eszopiclone |
Insomnia | VA Office of Research and Development |
February 25, 2021 | Phase 3 |
![]() |
---|
![]() |
![]() |